Skip to main content
Back
NKTR logo

Nektar Therapeutics

Data quality: 100%
NKTR
NASDAQ Healthcare Biotechnology
$74.34
▲ $2.12 (2.94%)
Mkt Cap: 1.51B
Day Range
$71.94 $74.49
52-Week Range
$6.45 $77.00
Volume
698,521
50D / 200D Avg
$56.05 / $44.68
Prev Close
$72.22

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E -9.2 0.4
P/B 16.8 2.9
ROE % -217.9 3.8
Net Margin % -297.1 3.9
Rev Growth 5Y % -14.2 10.0
D/E 1.7 0.2

Analyst Price Target

Hold
$136.40 +83.5%
Low: $105.00 High: $165.00
Forward EPS
-$10.10
Est. Revenue
41 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 -$10.44
-$12.84 – -$3.55
210 M 6
FY2029 -$12.81
-$15.75 – -$4.35
110 M 6
FY2028 -$12.96
-$19.89 – -$9.78
54 M 8

Key Takeaways

Revenue declined -14.20% annually over 5 years
Negative free cash flow of -208.68M
Revenue growth is decelerating — 1Y growth trails 5Y average by 29.69%
Capital efficient — spends only 0.31% of revenue on capex

Growth

Revenue Growth (5Y)
-14.20%
Revenue (1Y)-43.89%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-217.94%
ROIC-41.08%
Net Margin-297.07%
Op. Margin-236.77%

Safety

Debt / Equity
1.66
Current Ratio4.97
Interest Coverage-4.99

Valuation

P/E Ratio
-9.20
P/B Ratio16.80
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -43.89% Revenue Growth (3Y) -21.71%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -14.20% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 55.23M Net Income (TTM) -164.08M
ROE -217.94% ROA -58.51%
Gross Margin 100.00% Operating Margin -236.77%
Net Margin -297.07% Free Cash Flow (TTM) -208.68M
ROIC -41.08% FCF Growth (3Y) N/A
Safety
Debt / Equity 1.66 Current Ratio 4.97
Interest Coverage -4.99 Dividend Yield 0.00%
Valuation
P/E Ratio -9.20 P/B Ratio 16.80
P/S Ratio 27.32 PEG Ratio -0.36
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 1.51B Enterprise Value 1.64B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 55.23M 98.43M 90.12M 92.06M 101.91M
Net Income -164.08M -118.96M -276.06M -368.20M -523.84M
EPS (Diluted) -9.73 -8.68 -21.79 -29.51 -42.90
Gross Profit 55.23M 67.74M 53.48M 70.42M 77.01M
Operating Income -130.77M -105.20M -137.43M -240.24M -446.10M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 280.41M 303.85M 398.03M 710.60M 1.12B
Total Liabilities 190.57M 243.11M 267.05M 343.96M 437.68M
Shareholders' Equity 89.83M 60.74M 130.99M 366.64M 679.51M
Total Debt 148.91M 102.56M 117.78M 131.50M 143.18M
Cash & Equivalents 15.12M 44.25M 35.28M 88.23M 25.22M
Current Assets 266.27M 261.29M 330.70M 545.97M 795.58M
Current Liabilities 53.54M 61.40M 51.27M 68.20M 85.20M